By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is largely bearish on the current M&A wave in Big Pharma, citing high failure rates of bolt-on acquisitions, rising debt costs, and the risk of overpaying for assets. They also note that the current 'growth' narrative ignores the high probability of R&D failure and integration challenges.
Risk: High failure rates of bolt-on acquisitions (70-80%) and rising debt costs
Opportunity: Tightly aligned platform plays that unlock cross-asset synergies and faster cash flows
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributors Tyler Crowe, Matt Frankel, and Lou Whiteman take a dive into what’s driving the merger-and-acquisition frenzy, including:
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When you're ready to invest, check out this top 10 list of stocks to buy.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
A full transcript is below.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $398,052! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,181,688!
Now, it’s worth noting Stock Advisor’s total average return is 892% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 30, 2026. *
This podcast was recorded on June 23, 2026.
Tyler Crowe: Big pharma is in a buying mood today on Motley Fool Hidden Gems Investing. Welcome to Motley Fool Hidden Gems Investing. I'm your host, Tyler Crowe, and today I'm joined by longtime Fool contributors, Lou Whiteman and Matt Frankel. Now, it's Tuesday. I know the market. It's down quite a bit, I think, Nasdaq's down about 2% as we are taping. But hey, you know what? Volatile times. Markets are going to market.
Today, we're going to dive into the pharmaceutical industry and specifically the seemingly large wave of M&A that we've seen in recent months. We're also going to hit some mailbag questions specific to the pharmaceutical industry and look at some of the companies in this industry that we think are doing incredibly well. Now, at first, I thought this was some weird coincidence of seeing several deal announcements in the deal section of the Wall Street Journal recently, but so far, 2026 has been a banner year for M&A in the pharmaceutical industry. Here's a fascinating stack, guys, on this wave. So far this year, there have been more deals of $1 billion and more than all of 2025. Now, I'm sure there's lots of reasons we could go into a lot of them, but for each of you guys, what are some of the things that you're seeing that's driving this seemingly massive wave of consolidation, Lou?
Lou Whiteman: There's always a lot of reasons, as you say, but I do think there are a lot of trends just converging right now to fuel this consolidation. First, we have a looming patent cliff all over the industry. Pharmaceutical patents last 20 years. But because most of that time, usually more than half of that time is pre-revenue, the drug development stage, there's only really a short window for these companies to profit off of their creations, and as soon as it goes off patent, which means people can compete with you on this drug, you tend to see the revenue just drop orders of magnitude. There's an estimated $300 billion in annual revenue coming off patent in the next few years. That's prompting a lot of companies to either find bigger partners or if you're big enough, find new revenue streams. Hence, the M&A.
Look at Eli Lilly. They're a GLP-1 leader. They have a great portfolio. They are throwing all of the cash they're making into GLP-1s into a ton of deals, just trying to diversify their portfolio. Nature of biotech and pharmaceuticals is a lot of these won't work out, but if you cast your net wide enough, if you get good candidates, you might have the next big thing. Add in factors like regulatory pricing pressure, some interesting breakthroughs in areas like oncology and cardiology, this is an attractive market for both buyers and sellers, and I think we're seeing it play out.
Matt Frankel: You're right, Tyler. It has been a very active year for consolidation, just to add a little bit of context to that. We've already seen 32 separate deals worth $1 billion or more for a total deal value of $123 billion, and that's significant because if this continues, it would be the strongest year for M&A in the space. It's 2019, which was the strongest year ever. We're on pace for not quite a record year, but we're getting there.
Lou mentioned patent expiration is a big part of this. Almost 70 drugs that each generate over $1 billion of revenue have their patents expiring within the next couple of years. If you're not familiar, when their exclusivity period ends, it's not just that the revenue falls off a cliff. It really falls off a cliff. It could drop 80 to 90% overnight. Many companies are scrambling not only to replace the revenue, but the profits these are generating because generally, the patent-protected drugs are the highest margin part of these companies’ balance sheet.
One interesting observation is, as we mentioned, these are not giant acquisitions. There's been a shift to bolt on acquisitions from large mergers, focusing on assets that are saying late stage trials that could be integrated quickly into an established platform. That's one of the Eli Lilly acquisitions we just saw. Merck is another example. It's losing its patent protection for Keytruda, the blockbuster cancer drug, and it's made three major acquisitions in the last 10 months alone. You're seeing a lot of this from certain companies.
Tyler Crowe: It's not just them. Part of the reason I specifically saw this was in a matter of a couple of weeks, I saw, ABBV buying immunology company for about 10 billion. Glaxo Smith Klein was doing a $10 billion acquisition, and then Roche was even licensing drugs from other people. Mentioning Eli Lilly and Merck as well. It seems like everyone is incredibly active at this time, especially in the portfolio of developing drugs.
That's what I want to dig into a little bit deeper here. It's the regulatory part because it does look like there has been significant changes, at least in attitude in the FDA in recent months. Earlier, I think in the past couple of months or so, they basically reversed three decisions that were related to the treatments for rare and orphan diseases and we could get the long part, but the short version of is under the former FDA vaccine and biotech drug division leader, his name was Vinay Prasad, basically these drug candidates were rejected because the clinical study did not include comparisons to a placebo.
Now, placebo studies, they're not nearly as common and almost are pretty much unheard of in the rare disease area because one, the populations of these are so small, and two, there's off for life-threatening diseases. There's a very challenging almost ethical thing to saying we're going to put you on placebo. Look, I don't think it's a coincidence that we're seeing this rush to acquire clinical stage treatments, especially in oncology, rare diseases, a lot of those things that sometimes have a hard time getting through the FDA, at the exact same time that the FDA has signaled it's being more amenable to working with the industry lately.
Lou Whiteman: You're right. The placebo study method is not very practical or ethically defensible for rare diseases. After Prasad's departure, the FDA made it clear that they agree with that. Earlier this year, they issued some very significant policy updates, including a framework for sponsors of ultra-rare disease therapeutics to use alternative methods to build their approval cases as opposed to the placebo method. For a while, the regulatory environment essentially froze the market for these clinical-stage companies that were developing these rare disease treatments. It was perceived as if their development suddenly faced a moving target. With the FDA's recent reversals that you mentioned, those types of drug programs become immediately more valuable, and some are still marked down from what you would normally see them sell for, and you're seeing that help fuel the buying frenzy also.
Tyler Crowe: We were discussing this. Maybe it was back in January, maybe February, where there was this quote from the CEO of Moderna because they were trying to get a new combination COVID flu vaccine through. Basically, the CEO came out rather bluntly and was like, I don't even know if it's worth it to do clinical trials on vaccines right now because of the regulatory burden because, Lou, one thing that companies hate more than regulations is constantly moving and changing regulations.
Lou Whiteman: Especially in a business like this where you're spending so much on these trials and so much time in development for what is already a low success rate. If you start changing the targets and changing the game mid-game in a business where you already have huge failure rates, it's just going to create chaos. I love what we're doing here, but as an investor, I think it's worth noting that there's a needle-mover problem. By their nature, often drugs don't have a huge audience, and even at high prices, they're not massive revenue generators. It's more than just the common good. I'm definitely glad they're working on them. But the reason why they chase the blockbusters is, at the end of the day, it's the blockbusters that's solving these huge problems, whether it's cancer, whether it's heart disease. That's where you really move the needle.
Tyler Crowe: Coming up out for the break, we're going to take a look at the big pharma, what's doing well, what's not, and maybe uncover some of the hidden gems, perhaps in the pharmaceutical industry.
Guys, one of the perceptions of the pharmaceutical industry, or big pharma, by its big scary name, is that it's a relatively safe industry that's going to probably churn out cash for years on end. Many of the largest pharma companies are even known as large dividend payers that have been doing it for a long time. But I was doing a little bit of testing that theory this morning, and over the past 10 years, the results have not been as great as the industry's reputation. I think of the dozen largest pharma companies worldwide, only three have actually beaten the S&P 500 over the past decade. Granted, we have had a fantastic past decade for the S&P 500. It's a pretty high hurdle. Even Novo Nordisk, which at the time, for a short period, there had basically the monopoly on the GLP-1 drug market with Ozempic and some of its other treatments. It's now significantly trailed the market over the past 10 years as competitions come in, like Eli Lilly, as you mentioned.
But what's that old addage past performance doesn't necessarily guarantee future results. I want you guys to think about if we're looking at the pharmaceutical industry right now, who do you see as doing great and doing some work that really is needle-moving to your point, Lou, about some things doing well, some things actually as an investor, moving the needle, and some you're not necessarily certain about.
Lou Whiteman: Let's be honest, this is a terribly brutal industry. I would hate to buy an ETF for this industry and just track it. You really have to find individual winners who are in the right space here because with the costs, with the regulatory burden, it is hard for this industry to really deliver as a group over time. As far as who those gems might be, as I mentioned, Eli Lilly is driving a lot of consolidation. I don't think there's a better run big pharma right now, and I love that they are investing in their future, investing even beyond GLP-1s. I remember when statins were the miracle drug, and look, it was a great benefit to humanity, and it was a moneymaker for a while, but even statins didn't last forever. I love Lilly as looking past today. Lilly's boring, though.
If you want to dig down deeper, I want to give some love to United Therapeutics, ticker UTHR. This is a wreck in hidden gems and a number of services that has easily beaten the market in the last few years. Great story here, founded by Martine Rothblatt who also founded SiriusXM, real entrepreneur. Her daughter was diagnosed with a lung disease, her frustration of treatments and seeing, I guess, a market opportunity there. She's built this out. They have six FDA-approved treatments, a robust pipeline, just a great business run by an entrepreneur with a real cause driving her. Really interesting company.
Matt Frankel: I would second Eli Lilly as the one that's doing great. I can't think of one that I would rather mention. It does depend on its Tirzepatide, which is its version of GLP-1. Those are the Mounjaro and Zepbound brand names for more than half of its revenue. These are patented through 2036, and so Lilly has one of the most favorable patent-cliff exposures in the space. Even its next-generation GLP candidates are making excellent progress through the pipeline. As Lou mentioned, the company is wisely using its cash flow to make bolt-on acquisitions and gradually diversify away. Hopefully, in 10 years when the patent does expire, they're not just scrambling to do something. Speaking of scrambling to do something, I mentioned Merck earlier, and that's the one that I'm less certain about. The company has been extremely active in M&A. I mentioned three big deals in the last 10 months. But Keytruda makes up more than half of its revenue, and that patent goes away in 2028. The aggressive deal-making could work out, but that tight timeline, it really leaves little room for error.
Tyler Crowe: I want to interject myself here as well. Because it's the World Cup, and I feel like this actually ties into a fun World Cup story that maybe not everyone knows about, but everyone's heard the name Lionel Messi, probably one of the greatest footballers of all time. As a kid, he actually had a rare disease is basically where the glands that produce human growth hormones were not proficient, and he had to go on human growth hormones for much of his young life, and it's part of the reason he played for Barcelona because they were willing to pay for this very expensive treatment. It was a daily injection of synthetic growth hormone. It's an extremely burdensome thing for people who have this
Four leading AI models discuss this article
"The current M&A frenzy is likely unsustainable; rising debt costs, integration risk, and tighter regulation will cap upside, limiting durable value creation to only a few selective deals."
The article frames a booming M&A wave as a structural shift driven by patent cliffs and regulatory shifts. The strongest counterpoint is that this environment is expensive, highly levered, and dependent on fragile synergies from bolt-on deals. Debt-costs are rising, financing standards tightened, and antitrust scrutiny is sharper than in prior cycles, which could damp consolidation. Even if Lilly and Merck land strategic assets, many deals may fail to replace the lost patent-protected revenue, while pipelines and exclusivity windows add risk. The short-run market buoyancy could mask meaningful downside if integration or rate shocks derail expected ROIs.
Bullish counterpoint: a handful of high-quality bolt-ons with immediate revenue synergy could boost ROIC, validating the cycle. The real test is whether credit remains cheap and regulators stay permissive enough to avoid deal-blocking.
"The current M&A wave is a symptom of structural revenue decay, and the market is overestimating the ability of 'bolt-on' acquisitions to reliably replace blockbuster cash flows before patent expirations."
The current M&A frenzy in Big Pharma is less about innovation and more about 'defensive desperation' to fill revenue holes before the 2026-2028 patent cliff hits. While the regulatory environment has softened, allowing for easier clinical pathways, investors are ignoring the 'integration risk' of these bolt-on acquisitions. Buying growth through M&A is notoriously expensive and often destroys shareholder value due to overpayment and cultural friction. Eli Lilly (LLY) and Merck (MRK) are effectively paying a premium to delay the inevitable. I am neutral on the sector because the valuation multiples currently reflect a 'growth' narrative that ignores the high probability of R&D failure or integration bloat.
If the FDA’s new, more permissive regulatory framework for rare diseases creates a sustained pipeline of high-margin 'orphan' drugs, these companies could achieve higher terminal growth rates than the market currently prices in.
"Pharma M&A volume is high, but the success rate of bolt-on acquisitions is low, and companies like Merck (Keytruda patent cliff in 2028) are racing against time with little margin for error."
The article correctly identifies real tailwinds: $300B in patent cliffs, FDA regulatory thaw on rare diseases, and 32 deals worth $123B YTD. But it conflates activity with value creation. Bolt-on M&A in biotech is notoriously low-success—most pipeline acquisitions fail Phase 3 or post-approval. Eli Lilly's GLP-1 dominance is real, but the article ignores that Novo Nordisk's underperformance despite Ozempic dominance suggests even blockbuster franchises can't sustain valuations. The FDA's placebo-study reversal is positive for rare-disease developers, but ultra-rare drugs generate modest revenue. The real risk: big pharma is overpaying for clinical-stage assets in a rising-rate environment, betting on portfolio diversification when their core thesis—replacing lost revenue—remains unproven.
If FDA deregulation accelerates rare-disease approvals and Eli Lilly's acquisition strategy yields 2-3 genuine blockbusters by 2028-2030, the M&A wave becomes prescient capital deployment rather than panic buying. The article undersells how much dry powder and cash flow these companies have to absorb failed deals.
"Bolt-on acquisitions face clinical failure rates that make the M&A wave riskier than the patent-cliff narrative suggests."
The article frames 2026 pharma M&A as a rational response to $300B in looming patent expirations and a more flexible FDA, with Lilly positioned as the standout. Yet the shift to bolt-on deals in oncology and rare diseases ignores that these assets still face 70-80% clinical failure rates post-acquisition, and the FDA's recent reversals on placebo requirements could prove temporary if political pressure mounts. Merck's three deals in ten months to offset Keytruda's 2028 cliff exemplify the narrow margin for error. Historical data shows most bolt-ons fail to move the needle on revenue replacement.
If the FDA's new framework holds and even one or two Lilly or Merck acquisitions succeed, the current wave could deliver outsized returns faster than organic pipelines, validating the frenzy the article highlights.
"Macro-financing risk will determine whether bolt-on M&A delivers durable ROIC or just overpayment pressure."
Grok's 70-80% post-acquisition failure rate is a useful warning, but it understates the upside for tightly aligned platform plays that unlock cross-asset synergies and faster cash flows, especially in Lilly/Merck's rare-disease portfolios. The bigger risk is macro: rising rates and tighter credit could choke deal flow and force more overpayment pressure. If financing costs rise meaningfully, the M&A wave may not sustain.
"Big Pharma M&A is driven as much by the need to deploy stagnant cash piles efficiently as it is by the fear of patent cliffs."
Claude, you hit the nail on the head regarding Novo Nordisk, but you’re overlooking the tax-arbitrage motive. Big Pharma isn't just buying pipelines; they are optimizing global tax structures and leveraging massive cash piles that earn pathetic yields. If interest rates stay 'higher for longer,' sitting on $50B+ in cash is a drag on ROE. M&A is often a defensive hedge against cash-drag, not just a desperate attempt to plug the 2028 patent cliff.
"Tax arbitrage and cash drag are secondary; the core thesis—replacing patent-cliff revenue through high-risk bolt-ons—remains unproven and expensive."
Gemini's tax-arbitrage angle is real but overstated as a primary driver. If cash drag were the main motive, we'd see more dividend hikes or buybacks—cheaper than M&A integration risk. The tax play works only if deals are accretive post-tax; most bolt-ons aren't. The real issue: Gemini conflates 'we have cash' with 'M&A is rational.' Having $50B doesn't justify overpaying for 70-80% failure-rate assets. That's ROE destruction, not optimization.
"Rising rates make cash deployment via M&A costlier than buybacks, outweighing any tax optimization for high-risk bolt-ons."
Gemini's tax-arbitrage motive for cash piles ignores how higher-for-longer rates raise the true cost of capital for deploying those funds into 70-80% failure-rate assets. Even with $50B+ liquidity, Lilly and Merck face steeper hurdles for post-tax accretion when financing standards tighten and integration timelines stretch. This turns M&A from a hedge into amplified ROE risk if credit conditions worsen beyond current assumptions.
The panel is largely bearish on the current M&A wave in Big Pharma, citing high failure rates of bolt-on acquisitions, rising debt costs, and the risk of overpaying for assets. They also note that the current 'growth' narrative ignores the high probability of R&D failure and integration challenges.
Tightly aligned platform plays that unlock cross-asset synergies and faster cash flows
High failure rates of bolt-on acquisitions (70-80%) and rising debt costs